Mazitschek, Ralph, PhD

Phone: 617-643-6286
Lab: Mazitschek, Ralph


Dr. Mazitschek is an Assistant Professor at Harvard Medical School and Co-Director of the Chemical Biology Platform at the Center for Systems Biology at Massachusetts General Hospital (MGH). Dr. Mazitschek is also a member of the Infectious Diseases Initiative at The Broad Institute of Harvard and MIT, associate Faculty at the Center for Human Genetic Research at MGH and Visiting Scientist at the Department of Immunology and Infectious Diseases at Harvard School of Public Health.

Dr. Mazitschek graduated from the University of Leipzig in 2002 with a Ph.D. in Organic Chemistry. He continued hist research at the Institute of Chemistry and Cell Biology (ICCB) at Harvard Medical School first as postdoc and later as Institute Fellow, from which he joined the Chemical Biology Program at the newly founded Broad Institute of Harvard and MIT. In 2008 he joined the faculty of the Center for Systems Biology at the Massachusetts General Hospital to continue his independent research.


   Sort by:
Harada T, Ohguchi H, Grondin Y, Kikuchi S, Sagawa M, Tai YT, Mazitschek R, Hideshima T, Anderson KC
HDAC3 regulates DNMT1 expression in multiple myeloma: Therapeutic implications.
Leukemia. 2017;:ePub - PMID: 28490812 - PMCID: PMC5681897
Vinegoni C, Fumene Feruglio P, Brand C, Lee S, Nibbs AE, Stapleton S, Shah S, Gryczynski I, Reiner T, Mazitschek R, Weissleder R
Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging.
Nat Protoc. 2017;12(7):1472-1497 - PMID: 28686582
She A, Kurtser I, Reis SA, Hennig K, Lai J, Lang A, Zhao WN, Mazitschek R, Dickerson BC, Herz J, Haggarty SJ
Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia.
Cell Chem Biol. 2017;24(7):892-906.e5 - PMID: 28712747 - PMCID: PMC5695697
Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Oncotarget. 2017;8(46):80109-80123 - PMID: 29113288 - PMCID: PMC5655183
Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Oncotarget. 2017;:ePub - PMID: 28708596
Vunnam S, Mazitschek R, Kariem NM, Reddy A, Rabeh W, Li L, O'Connor MJ, Al-Tel TH
Modular Bi-Directional One-Pot Strategies for the Diastereoselective Synthesis of Structurally Diverse Collections of Constrained β-Carboline-Benzoxazepines.
Chemistry. 2017;23(57):14182-14192 - PMID: 28770556
Iaconelli J, Lalonde J, Watmuff B, Liu B, Mazitschek R, Haggarty SJ, Karmacharya R
Lysine Deacetylation by HDAC6 Regulates the Kinase Activity of AKT in Human Neural Progenitor Cells.
ACS Chem Biol. 2017;12(8):2139-2148 - PMID: 28628306
Krukowski K, Ma J, Golonzhka O, Laumet GO, Gutti T, van Duzer JH, Mazitschek R, Jarpe MB, Heijnen CJ, Kavelaars A
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Pain. 2017;158(6):1126-1137 - PMID: 28267067 - PMCID: PMC5435512
Randino R, Gazzerro P, Mazitschek R, Rodriquez M
Synthesis and biological evaluation of Santacruzamate-A based analogues.
Bioorg Med Chem. 2017;:ePub - PMID: 29100734
Vieson MD, Gojmerac AM, Khan D, Dai R, van Duzer JH, Mazitschek R, Caudell DL, Liao X, Luo XM, Reilly CM
Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice.
Histol Histopathol. 2017;:11885 - PMID: 28245046